UPLIZNA 10 MG
INEBILIZUMAB : 10 MG · DIN 02543931 · AMGEN CANADA INC
Health Canada status: MARKETED
What is UPLIZNA?
UPLIZNA 10 MG contains INEBILIZUMAB : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02543931, held by AMGEN CANADA INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 31-Mar-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is UPLIZNA used for?
Monotherapy for adult Neuromyelitis Optica Spectrum Disorder (NMOSD) (AQP4-IgG seropositive) and treatment of adult Immunoglobulin G4-related disease (IgG4-RD) to reduce flare frequency.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02543931 |
|---|---|
| Brand name | UPLIZNA |
| Generic / active ingredient | INEBILIZUMAB : 10 MG |
| Manufacturer | AMGEN CANADA INC |
| Strength | 10 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Schedule D |
| ATC code | L04AG10 INEBILIZUMAB |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 31-Mar-2025 |
How is it administered?
Initial: 300 mg IV infusion, followed 2 weeks later by 300 mg. Subsequent: 300 mg IV every 6 months. Administer over ~90 mins with premedication (corticosteroid, antihistamine, antipyretic).
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store prepared infusion solution for max 24 hours in refrigerator (2°C to 8°C) or 4 hours at room temperature (20°C to 25°C). Do not shake.
How is it supplied?
Carton containing three 100 mg/10 mL single-use vials.
Contraindications
Hypersensitivity; life-threatening infusion reaction to UPLIZNA; severe active infection (e.g., HBV); active/untreated latent TB; history of PML; severely immunocompromised; active malignancy.
Warnings and precautions
Risk of infusion reactions (including anaphylaxis), infections, late-onset neutropenia, HBV reactivation, PML, and reduction in immunoglobulins. Evaluate for TB before initiation.
Who else supplies INEBILIZUMAB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. INEBILIZUMAB appears in 3 registered pack listings across 3 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.